Neurocrine Biosciences (NBIX)
Health Care · biopharmaceuticals · NASDAQ
A neuroscience-focused biopharmaceutical company commercializing specialized treatments for neurological and endocrine disorders while advancing a diverse pipeline of therapeutic modalities.
What Neurocrine Biosciences does
Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company dedicated to developing treatments for neurological, psychiatric, endocrine, and immunological disorders. The company's commercial portfolio features FDA-approved therapies for conditions such as tardive dyskinesia, Huntington's disease chorea, congenital adrenal hyperplasia, and hyperphagia in Prader-Willi syndrome. It also maintains a diverse clinical pipeline spanning small molecules, biologics, and gene therapies.
Themes: neuroscience therapeutics, rare disease treatments, tardive dyskinesia, congenital adrenal hyperplasia, Prader-Willi syndrome, Huntington's disease chorea, drug development
Fundamentals
- Price$141.25 as of 2026-10-08 close
- Market cap$14.4B as of 2026-07-22 (share count; price 2026-10-08)
- 1-year return+1.6% 2025-10-08 close $139.08 → 2026-10-08 close $141.25
- P/E20.71 as of 2026-10-08
- Net margin+16.7% FY2025, SEC XBRL
- ROE+14.7% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-03
- Revenue growth (YoY)+34.4% as of 2026-09-03
- Revenue CAGR (3y)+24.3% SEC XBRL
- Beta0.78 as of 2026-09-03
- Last reported earnings2026-07-30 SEC EDGAR Form 8-K (Item 2.02)
How NBIX compares in its sector
- price-to-earnings ratiomiddle range 185 covered Health Care peers, as of 2026-10-08
- net profit margintop 25% 430 covered Health Care peers, as of 2026-09-03
- operating margintop 25% 417 covered Health Care peers, as of 2026-09-03
- return on equitytop 25% 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
NBIX is not currently in any published Top 10 list. Its scores are below.
Top 10 score
66.5 #75 of 1,379 scored · #10 of 151 in Health Care
Financial health 90th (debt to equity 0, free cash flow margin 26.2%) and growth 88th (revenue growth year over year 34.4%, 3-year revenue CAGR 24.3%); weakest is capital return (39th, consecutive years of dividend increases 0 years, net share count bought back over the year 1.2).
Scores as of 8 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
How Neurocrine Biosciences looks technically
Neurocrine Biosciences (NBIX) is trading 3.9% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 87 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 25, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 39, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 5 trading days ago (its momentum flipped positive). It made a new 20-day low about 8 trading days ago. It is 24.1% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 3.9% below its 200-day average, the long-term trend line — a long-term downtrend | -3.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $152.83 | $152.83 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $146.97 | $146.97 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 9 calendar days ago — the swings before that are what the structure reading is measured on | 9 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 136.31. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a five-part sequence in leg 4. | possible three-wave downward correction, complete (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 87 trading days ago — a "golden cross", a bullish long-term signal | 87 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 25, with sellers in control | 25.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 39, neither overbought (above 70) nor oversold (below 30) | 39.2 |
|---|---|---|
| Position in its 14-day range | it is trading around the middle of its 14-day range ($136.31 to $146.92) — its "stochastic" reading is 47 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 46.6 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 5 trading days ago (its momentum flipped positive) | 5 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $186.12 | $186.12 |
|---|---|---|
| From the 52-week high | it is 24.1% below its 52-week high (its highest price of the past year) | -24.1% |
| Above the 52-week low | it is 15.6% above its 52-week low (its lowest price of the past year) | +15.7% |
| Below the 52-week high | it is 24.1% below its highest point of the past year | 24.1% |
| Since a 20-day breakout | it made a new 20-day low about 8 trading days ago | 8 sessions |
| Since a 55-day breakout | it made a new 55-day low about 8 trading days ago | 8 sessions |
| All-time high | its highest closing price on record is $186.12 (set on 2026-07-30) | $186.12 |
| Given back of the 52-week move | over the past year its closes ranged ($123.10 to $185.50), and it has given back well over two thirds of its rise from last year’s low — 71% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $144.94 to $146.94. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 70.9% |
| From the all-time high | it is 24.1% below its all-time high | -24.1% |
| Nearest price level | it is sitting right on a resistance level at $141.91 — a price it turned at twice since 2025-12-19, most recently on 2026-02-10. Since 2024-10-08 it has 6 such levels below the current price and 5 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +0.5% |
| All-time low | its lowest closing price on record is $1.94 (set on 2009-11-30) | $1.94 |
| Above the all-time low | it is 7180.9% above its all-time low | +7,181% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 63rd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $3.99 between its high and its low — about 2.8% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $3.99 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $133.70 and $155.60 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $133.70 – $144.65 – $155.60 |
| Typical daily range (% of price) | its price moves about 2.8% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.8% |
| Stretch from the 200-day average | it is trading 1.4 daily ranges below its 200-day average price (3.9% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.4 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.97× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 0.3% since the prior reading | -0.3% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has improved toward "buy" since the prior reading | 0.01 toward buy |
Candlestick patterns
4
| Since a doji | 2 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 2 sessions ago |
|---|---|---|
| Since a hammer | 9 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 9 sessions ago |
| Since a bullish engulfing | 8 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 8 sessions ago |
| Since a bearish engulfing | 9 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 9 sessions ago |
Price gaps
1
| Gap at the open | it opened on 2026-10-08 0.4% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | -0.4% |
|---|
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -2.93% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 10.0 percentage points (the stock lost 8.9% while the market gained 1.0%) | -10.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 24.6 percentage points (the stock lost 20.8% while the market gained 3.8%) | -24.6% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 10.8 percentage points (the stock gained 6.6% while the market gained 17.5%) | -10.8% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 13.4 percentage points (the stock gained 1.6% while the market gained 15.0%) | -13.4% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, MACD momentum is positive — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 13% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 4.2% of the share price. | -12.6% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 4% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $147.42 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | -4.2% |
|---|---|---|
| Vs the average paid since it last reported | the price is 8% below the average price paid since it last reported on 2026-07-30 (its 8-K), so the typical buyer over that stretch is under water. That average is $152.99 — a volume-weighted average of daily closes over 50 sessions, not a true tick-by-tick VWAP. | -7.7% |
Price levels it has turned at before
NBIX last closed at $141.25 on 2026-10-08. Since 2024-10-08 it has turned at 6 prices below its last close and 5 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $141.91 | Resistance | 0.5% above the last close | turned there twice · 2025-12-19 to 2026-02-10 |
| $138.71 | Support | 1.8% below the last close | turned there six times · 2024-12-18 to 2026-01-23 |
| $134.81 | Support | 4.6% below the last close | turned there 9 times · 2025-07-15 to 2026-09-29 |
| $148.92 | Resistance | 5.4% above the last close | turned there three times · 2025-09-24 to 2026-08-14 |
| $129.77 | Support | 8.1% below the last close | turned there five times · 2024-10-30 to 2026-01-20 |
| $154.13 | Resistance | 9.1% above the last close | turned there four times · 2025-01-30 to 2026-06-16 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $136.31.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
Alternate reading: The same swings also read as a five-part sequence in leg 4, which fails on a close above $148.78.
This reading has stood for 3 trading days, since 2026-10-06.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · MACD just crossed bullish (12/26/9) · lagging the market · Under water since its last earnings report (below the anchored VWAP) · Trading below the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.41 mean, 1=Strong Buy…5=Strong Sell) — 29 analysts
- Mean price target$207.81 range $164.00 – $253.00; median $214.00
Analyst estimates, as of 2026-10-03. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for NBIX
- Consensus EPS estimate$2.74 next reporting period, as of 2026-10-03
- Estimate change, 30 days+$0.01944 (+0.7%) from $2.72, on 2026-08-29, 35-day window
- Readings revised upward38% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on a limited number of commercial products for the majority of revenue.","Risks associated with clinical trial success and regulatory approval processes for pipeline candidates."]
What changed in the latest 10-Q
AI-assisted comparison of NBIX's 10-Q filed 2026-05-05 against the prior one filed 2025-10-28.
Management's Discussion & Analysis (MD&A)
- Added:
- 2026 filing includes 'Business Highlights' for Q1 2026 covering net product sales increase of 43.9% to $811.0 million, Soleno Therapeutics acquisition for ~$2.9 billion announced in April 2026, sale of Neurocrine Group Limited to Immedica Pharma AB for $63.2 million completed January 21, 2026, and promotion of Andrew Ratz to Chief Technical Operations Officer
- 2026 filing includes specific Q1 2026 'Pipeline Highlights' with Phase 2 study of NBI-1117570, real-world INGREZZA vs AUSTEDO XR comparison data, tardive dyskinesia screening consensus recommendations for older adults, and two-year CRENESSITY pediatric data
- 2026 filing adds financial table for three months ended March 31, 2026 vs 2025 showing revenues, operating expenses, operating income, other income/expense, provision for taxes, and diluted earnings per share
- 2026 filing includes detailed Q1 2026 revenue breakdown: INGREZZA $656.9M, CRENESSITY $153.3M, Other $0.8M
- 2026 filing references financial statements for year ended December 31, 2025 instead of 2024
- Removed:
- 2025 filing's reference to Quarterly Report on Form 10-Q for six months ended June 30, 2025 is removed
- 2025 filing's phrase 'but few options' following 'people with great needs' is removed from company purpose statement
- 2025 filing's language stating 'neuropsychiatric, neurological, and neuroendocrine disorders' is replaced with 'neurological, psychiatric, endocrine, and immunological disorders'
- 2025 filing's phrase 'and gene therapy' is changed to 'and gene therapies'
- 2025 filing's detailed INGREZZA and CRENESSITY sales figures for nine-month periods and partnership details with MTPC/DYSVAL/REMLEAS and AbbVie/ORILISSA/ORIAHNN are removed
- 2025 filing's 'Business Highlights' covering February 2025 share repurchase program, January 2025 CMS small biotech exception notification, June 2025 CMO appointment, and planned sales team expansion are removed
- 2025 filing's extensive 2025 'Pipeline Highlights' covering Phase 3 studies for direclidine and osavampator, Phase 1 studies for NBIP-1435, NBI-921355, and NBI-1140675, KINECT-PRO Phase 4 data, SAVITRI Phase 2 data, and failed valbenazine schizophrenia Phase 3 study are removed
- Reworded:
- Company purpose changed from 'discovering and developing' to 'discovering, developing, and commercializing'
- Therapeutic area descriptions changed from 'neuropsychiatric, neurological, and neuroendocrine disorders' to 'neurological, psychiatric, endocrine, and immunological disorders'
- CAH description changed from 'classic congenital adrenal hyperplasia (CAH)' to 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (CAH)'
- 'gene therapy' changed to 'gene therapies' in pipeline modalities description
- Notes:
- Older filing (2025-10-28) presents nine-month and three-month data for periods ending September 30, 2025 and 2024; newer filing (2026-05-05) presents three-month data for periods ending March 31, 2026 and 2025—these are different reporting periods and not directly comparable quarters
- Older filing contains extensive forward-looking business and pipeline information for 2025; newer filing replaces this with Q1 2026 specific information—the differences largely reflect the passage of time and new developments rather than restatements of prior periods
Risk Factors
- Added:
- Added asterisk marking to 'We may not be able to continue to successfully commercialize INGREZZA or any of our product candidates if they are approved in the future.' in the detailed risk factors section (filed 2026-05-05)
- Added phrase 'and commercialize' after 'launch' in summary risk factor bullet point (filed 2026-05-05)
- Added reference to 'products' in licensing risk factor: 'We license some of our core technologies, drug leads, products, and product candidates from third parties' (filed 2026-05-05)
- Removed:
- Removed reference to '10-K for the fiscal year ended December 31, 2024' and replaced with '10-K for the fiscal year ended December 31, 2025' (filed 2026-05-05)
- Removed specific reference to 'tardive dyskinesia' and replaced with 'TD' abbreviation (filed 2026-05-05)
- Removed specific date reference 'September 2024' and replaced with 'first quarter of 2026' for sales team expansion (filed 2026-05-05)
- Removed phrase 'and distribution capabilities' from commercial infrastructure description (filed 2026-05-05)
- Removed specific reference to 'psychiatry and long-term care' sales teams (filed 2026-05-05)
- Removed phrase 'or be forced to pay damages' and replaced with 'or be required to pay damages' in licensing risk factor (filed 2026-05-05)
- Reworded:
- Changed 'We may not be able to successfully launch CRENESSITY' to 'We may not be able to successfully launch and commercialize CRENESSITY' in summary risk factors (filed 2026-05-05)
- Changed 'drug leads and candidates' to 'drug leads, products, and product candidates' in licensing risk factor (filed 2026-05-05)
- Changed 'or be forced to pay damages' to 'or be required to pay damages' in licensing risk factor (filed 2026-05-05)
- Notes:
- The newer filing text appears truncated at the end of the CRENESSITY risk factor discussion, making a complete comparison of that section uncertain
- The older filing text also appears truncated at the same location, limiting assessment of subsequent content changes
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 4 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 30 days · read to 2026-10-040 buys · 2 sells ($493335) — 2 selling insiders
- Last 90 days · read to 2026-10-040 buys · 4 sells ($1M) — 4 selling insiders
- Last 180 days · read to 2026-10-040 buys · 30 sells ($63M) — 11 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-14. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about NBIX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 2 matched disclosures for NBIX from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Institutional ownership (13F)
6 institutional 13F filers reported holding NBIX as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 21,097,927
- Reported value $3,555,739,131
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 5 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about NBIX's institutional holders → See what each manager we track holds →
Short interest (FINRA)
NBIX had 4,964,907 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
NBIX had 4.88% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.37 days to cover at the same settlement.
- Reported short interest (shares) 4,964,907
- Short interest (% of shares outstanding) 4.88%
- Prior settlement (shares) 5,056,144
- Reported change -1.8%
- Days to cover (reported) 5.37
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Teva Pharmaceutical Industries (TEVA)
- Acadia Pharmaceuticals (ACAD)
- AbbVie (ABBV)
- Amgen (AMGN)
- Biogen (BIIB)
- Sage Therapeutics
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare NBIX vs…
Neurocrine Biosciences is found in…
Frequently asked questions
What does Neurocrine Biosciences (NBIX) do?
Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company dedicated to developing treatments for neurological, psychiatric, endocrine, and immunological disorders. The company's commercial portfolio features FDA-approved therapies for conditions such as tardive dyskinesia, Huntington's disease chorea, congenital adrenal hyperplasia, and hyperphagia in Prader-Willi syndrome. It also maintains a diverse clinical pipeline spanning small molecules, biologics, and gene therapies.
What sector is Neurocrine Biosciences (NBIX) in?
Neurocrine Biosciences (NBIX) is classified in the Health Care sector. Its industry is biopharmaceuticals. It trades on NASDAQ.
Who are Neurocrine Biosciences's (NBIX) competitors?
Notable peers of Neurocrine Biosciences (NBIX) include Teva Pharmaceutical Industries, Acadia Pharmaceuticals, AbbVie, Amgen and Biogen. This peer set is informational only — not financial advice.
Has there been recent U.S. House stock trading in NBIX?
Yes — we hold 2 matched STOCK Act disclosures for NBIX from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Neurocrine Biosciences (NBIX) overbought or oversold right now?
Neurocrine Biosciences (NBIX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 39, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on NBIX come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.